nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.02.2012 | Focussed Research Review

Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte-induced split anergy in natural killer cells

verfasst von: Anahid Jewett, Han-Ching Tseng

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Cytotoxic function of NK cells is largely suppressed in the tumor microenvironment by a number of distinct effectors and their secreted factors. The aims of this review are to provide a rationale and a potential mechanism for immunosuppression in cancer and to demonstrate the significance of such immunosuppression in cellular differentiation and progression of cancer. We have recently shown that NK cells mediate significant cytotoxicity against primary oral squamous carcinoma stem cells (OSCSCs) as compared to their more differentiated oral squamous carcinoma cells. In addition, human embryonic stem cells, mesenchymal stem cells (hMSCs), dental pulp stem cells (hDPSCs) and induced pluripotent stem cells were all significantly more susceptible to NK-cell-mediated cytotoxicity than their differentiated counterparts or parental cells from which they were derived. We have also reported that inhibition of differentiation or reversion of cells to a less-differentiated phenotype by blocking NFκB significantly augmented NK-cell function. Total population of monocytes and those depleted of CD16(+) subsets were able to substantially suppress NK-cell-mediated lysis of OSCSCs, hMSCs and hDPSCs. Overall, our results suggest that stem cells but not their differentiated counterparts are significant targets of the NK-cell cytotoxicity. The concept of split anergy in NK cells and its contribution to cell differentiation, tissue repair and regeneration and in tumor resistance and progression will be discussed in this review.

Kolenko V, Wang Q, Riedy MC, O’Shea J, Ritz J, Cathcart MK, Rayman P, Tubbs R, Edinger M, Novick A, Bukowski R, Finke J (1997) Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 159(6):3057–3067PubMed

Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ (1997) T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40(1):113–119PubMed

Camp BJ, Dyhrman ST, Memoli VA, Mott LA, Barth RJ Jr (1996) In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol 3(2):176–184PubMedCrossRef

Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SY, Watanabe M, Gong J, Hayes DF, Kufe DW, Nadler LM (1996) Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2(12):1367–1370PubMedCrossRef

Bennett MW, O’Connell J, O’Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F (1998) The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160(11):5669–5675PubMed

Jewett A, Head C, Cacalano NA (2006) Emerging mechanisms of immunosuppression in oral cancers. J Dent Res 85(12):1061–1073PubMedCrossRef

Lindgren A, Yun CH, Sjoling A, Berggren C, Sun JB, Jonsson E, Holmgren J, Svennerholm AM, Lundin SB (2011) Impaired IFN-gamma production after stimulation with bacterial components by natural killer cells from gastric cancer patients. Exp Cell Res 317(6):849–858PubMedCrossRef

Tanaka H, Nakao M, Shichijo S, Itoh K (1995) Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. Cytokine 7(4):372–379PubMedCrossRef

Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, von Fliedner V (1988) Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res 48(24 Pt 1):6992–6998PubMed

10.

Qin J, Han B, Pang J (1997) The relationship between TIL from human primary hepatic carcinoma and prognosis. Zhonghua Yi Xue Za Zhi 77(3):167–170PubMed

11.

Han X, Papadopoulos AJ, Ruparelia V, Devaja O, Raju KS (1997) Tumor lymphocytes in patients with advanced ovarian cancer: changes during in vitro culture and implications for immunotherapy. Gynecol Oncol 65(3):391–398PubMedCrossRef

12.

Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4):1815–1822PubMedCrossRef

13.

Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem cells (Dayton, Ohio) 26(1):212–222CrossRef

14.

Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 111(3):1327–1333. doi:10.1182/blood-2007-02-074997 PubMedCrossRef

15.

Jewett A, Bonavida B (1996) Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol 156(3):907–915PubMed

16.

Jewett A, Bonavida B (1995) Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol 160(1):91–97PubMedCrossRef

17.

Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P, Kiessling R (1993) Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53(23):5610–5612PubMed

18.

Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, Herschman HR, Cacalano N, Pyle AD, Park NH, Jewett A (2010) Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One 5(7):e11590PubMedCrossRef

19.

Vuk-Pavlovic S (2008) Rebuilding immunity in cancer patients. Blood Cells Mol Dis 40(1):94–100PubMedCrossRef

20.

Greten TF, Manns MP, Korangy F (2011) Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 11(7):802–806PubMedCrossRef

21.

Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25(18):2546–2553. doi:10.1200/JCO.2006.08.5829 PubMedCrossRef

22.

Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R (2010) Immature immunosuppressive CD14 + HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70(11):4335–4345. doi:10.1158/0008-5472.CAN-09-3767 PubMedCrossRef

23.

Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796(1):11–18PubMed

24.

Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22(2):231–237PubMedCrossRef

25.

Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y (2011) The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 93(3):294–300PubMedCrossRef

26.

Jewett A, Arasteh A, Tseng HC, Behel A, Arasteh H, Yang W, Cacalano NA, Paranjpe A (2010) Strategies to rescue mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs) from NK cell mediated cytotoxicity. PLoS One 5(3):e9874PubMedCrossRef

27.

Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1–27PubMed

28.

Burnet FM (1971) Immunological surveillance in neoplasia. Transplant Rev 7:3–25PubMed

29.

Burnet FM (1971) Implications of immunological surveillance for cancer therapy. Isr J Med Sci 7(1):9–16PubMed

30.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998PubMedCrossRef

31.

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148PubMedCrossRef

32.

Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, Kunisada T, Mori H, Iwama T (2007) VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 360(3):553–559PubMedCrossRef

33.

Inagaki A, Soeda A, Oka N, Kitajima H, Nakagawa J, Motohashi T, Kunisada T, Iwama T (2007) Long-term maintenance of brain tumor stem cell properties under at non-adherent and adherent culture conditions. Biochem Biophys Res Commun 361(3):586–592PubMedCrossRef

34.

Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S, Nakashima S, Kunisada T, Iwama T (2008) Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem 283(16):10958–10966PubMedCrossRef

35.

Jewett A, Wang MY, Teruel A, Poupak Z, Bostanian Z, Park NH (2003) Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells. Hum Immunol 64(5):505–520PubMedCrossRef

36.

Murakami J, Asaumi J, Kawai N, Tsujigiwa H, Yanagi Y, Nagatsuka H, Inoue T, Kokeguchi S, Kawasaki S, Kuroda M, Tanaka N, Matsubara N, Kishi K (2005) Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemother Pharmacol 56(1):22–28PubMedCrossRef

37.

Murakami J, Asaumi J, Maki Y, Tsujigiwa H, Nagatsuka H, Kokeguchi S, Inoue T, Kawasaki S, Tanaka N, MacPhee D, Matsubara N, Kishi K (2004) Influence of CpG island methylation status in O6-methylguanine-DNA methyltransferase expression of oral cancer cell lines. Oncol Rep 12(2):339–345PubMed

38.

Abdulkarim B, Sabri S, Deutsch E, Chagraoui H, Maggiorella L, Thierry J, Eschwege F, Vainchenker W, Chouaib S, Bourhis J (2002) Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21(15):2334–2346PubMedCrossRef

39.

Jewett A, Cacalano NA, Teruel A, Romero M, Rashedi M, Wang M, Nakamura H (2006) Inhibition of nuclear factor kappa B (NFkappaB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation. Cancer Immunol Immunother 55(9):1052–1063PubMedCrossRef

40.

Pasparakis M, Courtois G, Hafner M, Schmidt-Supprian M, Nenci A, Toksoy A, Krampert M, Goebeler M, Gillitzer R, Israel A, Krieg T, Rajewsky K, Haase I (2002) TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417(6891):861–866PubMedCrossRef

41.

Berlin AL, Paller AS, Chan LS (2002) Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology. J Am Acad Dermatol 47(2):169–187 (quiz 188–190)PubMedCrossRef

42.

Seitz CS, Lin Q, Deng H, Khavari PA (1998) Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 95(5):2307–2312PubMedCrossRef

43.

Van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R (1999) Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59(14):3299–3303PubMed

44.

Van Hogerlinden M, Rozell BL, Toftgard R, Sundberg JP (2004) Characterization of the progressive skin disease and inflammatory cell infiltrate in mice with inhibited NF-kappaB signaling. J Invest Dermatol 123(1):101–108PubMedCrossRef

45.

Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10(1):48–54PubMedCrossRef

46.

Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21(55):8404–8413PubMedCrossRef

47.

Hu PF, Hultin LE, Hultin P, Hausner MA, Hirji K, Jewett A, Bonavida B, Detels R, Giorgi JV (1995) Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56− cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol 10(3):331–340PubMed

48.

Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL (1996) Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2(1):161–173PubMed

49.

Kuss I, Saito T, Johnson JT, Whiteside TL (1999) Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 5(2):329–334PubMed

50.

Patankar MS, Jing Y, Morrison JC, Belisle JA, Lattanzio FA, Deng Y, Wong NK, Morris HR, Dell A, Clark GF (2005) Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol 99(3):704–713

51.

Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL (1999) Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci USA 96(10):5640–5644PubMedCrossRef

52.

Jewett A, Gan XH, Lebow LT, Bonavida B (1996) Differential secretion of TNF-alpha and IFN-gamma by human peripheral blood-derived NK subsets and association with functional maturation. J Clin Immunol 16(1):46–54PubMedCrossRef

53.

Jewett A, Cavalcanti M, Bonavida B (1997) Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol 159(10):4815–4822PubMed

54.

Ortaldo JR, Mason AT, O’Shea JJ (1995) Receptor-induced death in human natural killer cells: involvement of CD16. J Exp Med 181(1):339–344PubMedCrossRef

55.

Azzoni L, Anegon I, Calabretta B, Perussia B (1995) Ligand binding to Fc gamma R induces c-myc-dependent apoptosis in IL-2-stimulated NK cells. J Immunol 154(2):491–499PubMed

56.

Jewett A, Cacalano NA, Head C, Teruel A (2006) Coengagement of CD16 and CD94 receptors mediates secretion of chemokines and induces apoptotic death of naive natural killer cells. Clin Cancer Res 12(71):1994–2003PubMedCrossRef

57.

Jewett A, Teruel A, Romero M, Head C, Cacalano N (2008) Rapid and potent induction of cell death and loss of NK cell cytotoxicity against oral tumors by F(ab’)2 fragment of anti-CD16 antibody. Cancer Immunol Immunother 57(7):1053–1066PubMedCrossRef

58.

Bonavida B, Lebow LT, Jewett A (1993) Natural killer cell subsets: maturation, differentiation and regulation. Natl Immun 12(4–5):194–208

59.

Bonavida B, Braquet M, Lebow LT, Jewett A (1994) Qualitative and quantitative analysis of subpopulations of cytotoxic effector cells by flow cytometry. J Lipid Mediat Cell Signal 9(1):19–25PubMed

60.

Jewett A, Bonavida B (1994) Activation of the human immature natural killer cell subset by IL-12 and its regulation by endogenous TNF-alpha and IFN-gamma secretion. Cell Immunol 154(1):273–286PubMedCrossRef

61.

Jewett A, Bonavida B (1995) Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol 15(1):35–44PubMedCrossRef

62.

Jewett A, Bonavida B (2000) MHC-Class I antigens regulate both the function and the survival of human peripheral blood NK cells: role of endogenously secreted TNF-alpha. Clin Immunol 96(1):19–28PubMedCrossRef

63.

Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633–640PubMedCrossRef

64.

Nemeth E, Baird AW, O’Farrelly C (2009) Microanatomy of the liver immune system. Semin Immunopathol 31(3):333–343PubMedCrossRef

Titel: Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte-induced split anergy in natural killer cells
verfasst von: Anahid Jewett
Han-Ching Tseng
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2012
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1163-7

Springer Medizin

Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte-induced split anergy in natural killer cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory

Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients

Regulatory dendritic cells in the tumor immunoenvironment

Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells

Immunological monitoring of the tumor immunoenvironment for clinical trials

Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie